NBTX Latest Press Releases

-- October 24, 2026 --

NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma Globe Newswire 6:59 AM

-- October 1, 2026 --

NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer Globe Newswire 4:15 PM

-- September 24, 2026 --

NANOBIOTIX Provides First Half 2026 Operational and Financial Update Globe Newswire 4:15 PM

-- September 22, 2026 --

Voting Rights and Shares Capital of the Company Globe Newswire 4:15 PM

-- September 14, 2026 --

NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer Globe Newswire 2:00 AM

-- September 9, 2026 --

NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference Globe Newswire 4:15 PM

-- August 25, 2026 --

Voting Rights and Shares Capital of the Company Globe Newswire 4:15 PM

-- July 30, 2026 --

Voting Rights and Shares Capital of the Company Globe Newswire 4:15 PM

Market Data Delayed 15 Minutes